By Laurie Watanabe | December 1, 2021SMA: What’s Next? New treatments are impacting what to expect for spinal muscular atrophy patients.
By Laurie Watanabe | November 23, 2021Study: Saliva Test Can Detect SMA Researchers say this new non-invasive test for spinal muscular atrophy could be performed in everyday locations.
By Laurie Watanabe | February 25, 2021Cure SMA Announces 2021 Summit of Strength Events In-person events are free to attend and offer education on spinal muscular atrophy issues.
By Laurie Watanabe | July 13, 2020Cure SMA: More than Half of U.S. States Now Screening Newborns Spinal muscular atrophy is the leading genetic cause of death in newborns worldwide.
By Laurie Watanabe | June 3, 2020Cure SMA’s 2020 Virtual Conference Is Next Week Registration for the consumer and the researcher tracks is free.
By Laurie Watanabe | February 19, 2020Cure SMA Announces 2020 Walk-n-Roll Events Fundraising series is expected to raise $1.7 million to support spinal muscular atrophy research.
By Mobility Management | December 4, 2019Cure SMA Plans 2020 Summit of Strength Events One-day conferences focus on support and education for people living with spinal muscular atrophy.
By Laurie Watanabe | September 1, 2019SMA’s New Horizons Editor’s Note: How new treatments for spinal muscular atrophy could impact future CRT provisions.
By Laurie Watanabe | August 7, 2019FDA: Data Related to SMA Drug Zolgensma Was Manipulated Manufacturer AveXis knew data had been manipulated, didn’t inform FDA until after drug was approved, FDA says.
